父亲亚临床甲状腺功能减退症影响体外受精/卵胞浆内单精子注射的临床结局
这项回顾性研究纳入2511对接受体外受精/卵胞浆内单精子注射(IVF/ICSI)的夫妇,父亲甲状腺功能正常组2282对、亚临床甲状腺功能减退症(SCH)组229对。调整混杂因素后,父亲SCH组的临床妊娠率和着床率显著低于甲状腺功能正常组,且差异仅在年龄≥35岁男性中显著。
要点
- 父亲SCH组调整后临床妊娠率0.32 vs 甲状腺功能正常组0.42,p=0.009。
- 父亲SCH组调整后着床率0.24 vs 甲状腺功能正常组0.29,p=0.037。
- 上述差异仅在男性年龄≥35岁组显著,<35岁组不显著。
核心结论
- 父亲SCH与IVF/ICSI后较差的临床结局相关,但这一不利影响仅见于年龄≥35岁的男性。
- 作者认为需要前瞻性研究和基础研究来分别证实这些结果和阐明相关机制。
研究设计与样本
- 回顾性研究,纳入2017年4月1日至2019年9月30日在本诊所因不孕接受治疗的2511对夫妇,父亲甲状腺功能正常组2282对、SCH组229对。
- 主要结局为受精率和临床妊娠率;次要结局为优质胚胎率、囊胚形成率、着床率和早期流产率,调整多种潜在混杂因素后进行比较。
主要发现
- 父亲甲状腺功能正常组与SCH组平均父亲年龄分别为34.5岁和36.0岁(p=0.002)。
- 两组精液参数和精子DNA碎片指数相似(所有p>0.05)。
- 调整后受精率(0.69 vs 0.71,p=0.30)、优质胚胎率(0.49 vs 0.52,p=0.31)、囊胚形成率(0.51 vs 0.53,p=0.57)和早期流产率(0.11 vs 0.10,p=0.81)在两组间相似。
- 父亲SCH组调整后临床妊娠率[置信区间,CI]为0.32[0.26-0.40],甲状腺功能正常组为0.42[0.40-0.45],p=0.009。
- 父亲SCH组调整后着床率[CI]为0.24[0.19-0.29],甲状腺功能正常组为0.29[0.27-0.31],p=0.037。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Maternal subclinical hypothyroidism (SCH) is a risk factor for adverse pregnancy outcomes. However, it is still unclear whether SCH affects male fertility. The aim of this study was to determine the association between paternal SCH and clinical outcomes after in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). Methods: This retrospective study included 2511 couples with paternal euthyroidism (n = 2282) or SCH (n = 229) who visited our clinic for infertility treatment between April 1, 2017, and September 30, 2019. The primary outcomes were the fertilization rate and clinical pregnancy rate; the secondary outcomes were the good-quality embryo rate, blastocyst formation rate, implantation rate, and early miscarriage rate. These outcomes were compared between the euthyroid and the SCH groups after adjusting for various potential confounders. Results: The mean paternal ages in the euthyroid and SCH groups were 34.5 and 36.0 years, respectively (p = 0.002). Semen parameters and sperm DNA fragmentation index were similar between the two groups (all p > 0.05). The adjusted fertilization (0.69 vs. 0.71, p = 0.30), good-quality embryo (0.49 vs. 0.52, p = 0.31), blastocyst formation (0.51 vs. 0.53, p = 0.57), and early miscarriage (0.11 vs. 0.10, p = 0.81) rates were also similar between the two groups. There was a significantly decreased adjusted clinical pregnancy rate [confidence interval, CI] and implantation rate [CI] in the paternal SCH group compared with the euthyroid group (0.32 [0.26-0.40] vs. 0.42 [0.40-0.45], p = 0.009 for the clinical pregnancy rate; 0.24 [0.19-0.29] vs. 0.29 [0.27-0.31], p = 0.037 for the implantation rate). Stratified analysis indicated that these differences were only significant in men aged ≥35 years (p = 0.009 and 0.022, respectively) and not in men <35 years (p = 0.39 and 0.45, respectively). Conclusions: Paternal SCH was associated with worse clinical outcomes after IVF/ICSI, whereas this detrimental impact was only present in males ≥35 years old. Prospective studies and basic research are warranted to confirm these results and to clarify the mechanisms underlying these associations, respectively.
引用
- Rao M, Yang Z, Su C, et al. Paternal Subclinical Hypothyroidism Affects the Clinical Outcomes of In Vitro Fertilization/Intracytoplasmic Sperm Injection. Thyroid. 2020. PMID: 32600220. doi:10.1089/thy.2020.0154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。